Effects of selective serotonin reuptake inhibitors on rating-scale-assessed suicidality in adults with depression
Artikel i vetenskaplig tidskrift, 2018

Background Selective serotonin reuptake inhibitors (SSRIs) have been claimed to elicit or aggravate suicidal ideation. Aims To explore the effect of SSRIs on the suicidality item of the Hamilton Rating Scale for Depression (HRSD). Method We undertook a patient-level mega-analysis of adults with depression participating in industry-sponsored studies of sertraline, paroxetine or citalopram, comparing patients on an SSRI (n = 5681) with those on placebo (n = 2581) with respect to HRSD-rated suicidality. Separate analyses were conducted for young adults (age 18-24; n = 537) and adults (age = 25; n = 7725). Results Among adults, the reduction in mean rating of suicidality was larger and the risk for aggravation of suicidality lower in patients receiving an SSRI from week 1 and onwards. In young adults, SSRI treatment neither reduced nor increased suicidality ratings relative to placebo at the end-point. Conclusions The net effect of SSRIs on suicidality appears beneficial in people above the age of 24 and neutral in those aged 18-24.

Författare

Jakob Naslund

Göteborgs universitet

Fredrik Hieronymus

Göteborgs universitet

Alexander Lisinski

Göteborgs universitet

Staffan Nilsson

Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik

Elias Eriksson

Göteborgs universitet

British Journal of Psychiatry

0007-1250 (ISSN) 1472-1465 (eISSN)

Vol. 212 148-154

Ämneskategorier

Geriatrik

Övrig annan medicin och hälsovetenskap

Psykiatri

DOI

10.1192/bjp.2017.24

PubMed

29436321